Personalis, Inc.: insider trades · United States · SEC (Form 4)

About Personalis, Inc.

Personalis, Inc. is a U.S.-based precision genomics company listed on the NASDAQ (United States) under the ticker PSNL. Founded in 2011 by a team of next-generation sequencing leaders from Stanford, the company has built a differentiated position in precision oncology by focusing on deep molecular profiling of cancer and the immune response. Personalis is now headquartered in Fremont, California, where it operates a CLIA-certified, CAP-accredited laboratory. Its business model sits at the intersection of clinical genomics, biopharma services, and biomarker-driven oncology, making it a specialized player rather than a broad-based diagnostics company. ([investors.personalis.com](https://investors.personalis.com/?utm_source=openai)) The company’s core franchise is the NeXT platform, which is designed to generate highly comprehensive genomic and immune-based data from tumor samples. Personalis’ product and service portfolio includes NeXT Dx for comprehensive tumor profiling, ImmunoID NeXT for tumor and microenvironment characterization, and NeXT Personal MRD for ultrasensitive detection of minimal residual disease and cancer recurrence. In addition to these clinical and translational offerings, Personalis provides sequencing and biomarker services to biopharmaceutical customers for clinical trials, companion diagnostic development, and research programs. This mix gives the company exposure to both research-stage demand and the increasingly important clinical diagnostics market. ([investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-inc-announces-launch-next-dxtm-test-comprehensive?utm_source=openai)) From a competitive standpoint, Personalis operates in a crowded and fast-moving market that includes molecular diagnostics companies, NGS platform providers, and oncology testing specialists. Its main differentiators are the breadth of its genomic coverage, the integration of tumor and immune-system information, and a long track record working with drug developers. The company has highlighted relationships with Moderna, Merck, Tempus, and the VA Million Veterans Program, which underscores both the quality of its scientific platform and the importance of strategic partnerships to its growth strategy. At the same time, those relationships also highlight customer concentration and execution risk. ([investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-reports-fourth-quarter-and-full-year-2025-results-and?utm_source=openai)) Recent developments suggest that Personalis is increasingly transitioning from a research-enablement story toward a clinical-commercial execution story. In its latest public updates, the company emphasized strong growth in clinical test volumes, milestone Medicare coverage wins for breast cancer recurrence surveillance and stage I-III NSCLC, and an expanded agreement with Tempus to market NeXT Personal Dx in colorectal cancer. Management also announced a CEO retirement and transition, with founder John West stepping back after a long career in DNA sequencing. For investors, PSNL remains a high-risk, catalyst-driven NASDAQ name: the upside depends on reimbursement, clinical adoption, and the ability to turn its scientific differentiation into sustainable revenue growth. ([investors.personalis.com](https://investors.personalis.com/node/8851/pdf?utm_source=openai))